CLADRIBINE INJECTION DIN 02319918
Health Canada record
| Active ingredient(s) | CLADRIBINE 1 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01BB04 CLADRIBINE |
| Original market date | 30-Jun-2009 |
| Current status date | 22-Aug-2016 |
| Source | Health Canada DPD |
Establishment licence of the holder
Fresenius Kabi Canada Ltd. — licence 102232, currently licensed, last inspection rating C (2025-10-01).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CLADRIBINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02553295 | APO-CLADRIBINE | APOTEX INC | Tablet | CLADRIBINE 10 MG | Marketed |
| 02566443 | AURO-CLADRIBINE | AURO PHARMA INC | Tablet | CLADRIBINE 10 MG | Marketed |
| 02494574 | CLADRIBINE INJECTION | GENERIC MEDICAL PARTNERS INC | Solution | CLADRIBINE 1 MG | Marketed |
| 02470179 | MAVENCLAD | EMD SERONO, A DIVISION OF EMD INC., CANADA | Tablet | CLADRIBINE 10 MG | Marketed |
| 02022117 | LEUSTATIN 1MG/ML | JANSSEN INC | Solution | CLADRIBINE 1 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 18161 | 2016-06-07 | Supplement to an Abbreviated New Drug Submission (SANDS) | CHANE IN MANUFACTURING PROCESS |
| 16823 | 2015-04-21 | Abbreviated New Drug Submission (ANDS) | MANUFACTURER AND PRODUCT NAME CHANGE |
| 9922 | 2008-12-04 | Abbreviated New Drug Submission (ANDS) |
International API supply for CLADRIBINE
5 valid EDQM Certificates of Suitability from 5 holders. 10 active FDA Drug Master Files.
Request a quote for CLADRIBINE INJECTION